Public Employees Retirement Association of Colorado decreased its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 0.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 43,117 shares of the biopharmaceutical company’s stock after selling 42 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Alexion Pharmaceuticals were worth $5,246,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Macquarie Group Ltd. boosted its position in shares of Alexion Pharmaceuticals by 15.6% in the fourth quarter. Macquarie Group Ltd. now owns 93,798 shares of the biopharmaceutical company’s stock valued at $11,476,000 after buying an additional 12,639 shares in the last quarter. Chevy Chase Trust Holdings Inc. boosted its position in shares of Alexion Pharmaceuticals by 3.0% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 194,440 shares of the biopharmaceutical company’s stock valued at $23,574,000 after buying an additional 5,619 shares in the last quarter. Rathbone Brothers plc boosted its position in shares of Alexion Pharmaceuticals by 5.3% in the first quarter. Rathbone Brothers plc now owns 1,990 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 100 shares in the last quarter. Gulf International Bank UK Ltd boosted its position in shares of Alexion Pharmaceuticals by 5.2% in the first quarter. Gulf International Bank UK Ltd now owns 70,627 shares of the biopharmaceutical company’s stock valued at $8,562,000 after buying an additional 3,480 shares in the last quarter. Finally, National Pension Service boosted its position in shares of Alexion Pharmaceuticals by 7.6% in the first quarter. National Pension Service now owns 178,199 shares of the biopharmaceutical company’s stock valued at $21,755,000 after buying an additional 12,513 shares in the last quarter. 94.37% of the stock is owned by institutional investors.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at 136.64 on Friday. The stock’s 50 day moving average price is $125.22 and its 200-day moving average price is $122.56. The firm has a market cap of $30.50 billion, a P/E ratio of 59.25 and a beta of 1.41. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $145.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The firm had revenue of $912 million for the quarter, compared to analysts’ expectations of $846.15 million. During the same quarter in the prior year, the firm earned $1.13 EPS. The business’s revenue for the quarter was up 21.1% compared to the same quarter last year. On average, analysts predict that Alexion Pharmaceuticals, Inc. will post $5.55 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Public Employees Retirement Association of Colorado Decreases Stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)” was first published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/05/public-employees-retirement-association-of-colorado-decreases-stake-in-alexion-pharmaceuticals-inc-nasdaqalxn.html.

Several equities analysts have recently weighed in on ALXN shares. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 18th. Cowen and Company reaffirmed an “outperform” rating and set a $180.00 price target on shares of Alexion Pharmaceuticals in a research note on Friday, April 28th. BMO Capital Markets reaffirmed an “outperform” rating and set a $158.00 price target on shares of Alexion Pharmaceuticals in a research note on Monday, May 1st. Barclays PLC reissued an “overweight” rating and issued a $155.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Finally, Raymond James Financial, Inc. reissued a “strong-buy” rating and issued a $176.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday, May 9th. Five equities research analysts have rated the stock with a hold rating, twenty have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $156.89.

In related news, Director Ann M. Veneman sold 700 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $137.74, for a total transaction of $96,418.00. Following the sale, the director now owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of the company’s stock in a transaction that occurred on Wednesday, June 14th. The shares were bought at an average cost of $116.32 per share, for a total transaction of $156,910,445.60. The disclosure for this purchase can be found here. Insiders have bought a total of 2,019,734 shares of company stock worth $235,606,846 in the last ninety days. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.